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ince depression,like chronic pain and anxiety,
is characterized by fluctuations in course and sponta-
neous improvements and features “distress” as a key
symptom, it is not surprising that it is also a placebo-
responsive condition.
1 The mean response rates for
placebo in antidepressant clinical trials range between
30% and 40%.
2,3 In this review, we describe the histori-
cal views of placebo, the associated terminology, the
proposed mechanisms underlying placebo response,and
the predictors of placebo response in depressed
patients. We further discuss patterns of placebo
response in depression,placebo response in antidepres-
sant clinical trials, the suggested strategies to minimize
it,and the ethical issues associated with the administra-
tion of placebo.
History
The word placebo derives from the Latin word placere,
which literally means “to please.”
4,5 First used in Western
medicine in the 1700s, the term placebo was defined in
the 1785 edition of Motherby's New Medical Dictionary
as a “commonplace method or medicine.”
6 In 1811,
Hooper’s Medical Dictionary defined placebo as “an
epithet given to any medicine adopted to please rather
than to benefit the patient.”
6 In 1958,the term appeared
in the English Psychiatric Dictionary as “a preparation
containing no medicine (or no medicine related to the
complaint) and administered to cause the patient to
believe that he is receiving treatment.”
4 Shapiro sug-
gested that most of the practice of medicine until the
17th century was an exploitation of placebo effects.
5,6
Definitions and terminology
Shapiro defined a placebo as “any therapy or compo-
nent of therapy that is deliberately used for its nonspe-
cific, psychological, or psychophysiological effects, or
that is used for its presumed specific effect, but is with-
out specific activity for the condition being treated”and
105
Placebo response in depression
Shamsah B.Sonawalla,MD;Jerrold F.Rosenbaum,MD
Clinical research
Keywords: placebo; placebo pattern response; true drug response; depression;
clinical trials
Address for correspondence: Shamsah B. Sonawalla, MD, Department of
Psychiatry, Massachusetts General Hospital, 15 Parkman Street, WAC 812,
Boston, MA 0211, USA
(e-mail: ssonawalla@partners.org)
Author affiliations: Department of Psychiatry, Massachusetts General Hos-
pital, Harvard Medical School, Boston, Mass, USA
With its naturally fluctuating course, depression is a high-
ly placebo-responsive condition: mean placebo response
rates in antidepressant clinical trials are 30% to 40%. We
review the history and terminology of placebo and the
proposed mechanisms underlying the placebo response,
including the physician–patient relationship and biologi-
cal, sociocultural, and treatment situation factors. We
identify the predictors and patterns of placebo response
in depressed patients, both within and outside of the clin-
ical trial context, and differentiate between true drug
response and placebo pattern response. We discuss the
strategies now being advanced to minimize the placebo
response given the increased placebo drift reported in
recent trials, and the ethical guidelines governing place-
bo administration. Potential areas for future research
include the identification of biological markers of place-
bo response, such as functional neuroimaging and quan-
titative electroencephalography, the development and
testing of more sophisticated, alternative research
designs, and the design of valid biological tools to assess
antidepressant efficacy.
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Salso noted that “specific activity is the therapeutic influ-
ence attributable solely to the contents or processes of
the therapies rendered [and] should be based on scien-
tifically controlled studies.”
6,7
Brody defined placebo as “a form of medical therapy,or
an intervention designed to simulate medical therapy,
that at the time of use is believed not to be a specific
therapy for the condition for which it is offered and that
is used either for its psychological effect or to eliminate
observer bias in an experimental setting; [or is] a form
of medical therapy now believed to be inefficacious,
though believed efficacious at the time.”
8
Placebo effect
There is a distinction between a “true placebo effect”ver-
sus a “perceived placebo effect.”
9 A true placebo effect
depends on factors such as the attitudes of the physician
and the patient, the suggestibility of the patient, and the
type of treatment.
9 A perceived placebo effect results
from the influence of such factors as the natural course of
the disease, the tendency of most measures of biological
variation to regress toward the mean, and unidentified
parallel interventions (eg, patients receiving extra atten-
tion during a clinical trial, becoming more aware of the
problem,and taking actions that influence outcome).
9
Placebo response
Placebo response represents the apparent improvement
in the clinical condition of patients randomly assigned
to placebo treatment (eg, a change within the placebo
group from pretreatment to posttreatment).
10 This
change may be due to an effect of placebo,but not nec-
essarily so, as in the case of spontaneous remission.
4
Also,a substantial portion of the placebo response (the
improvement that occurs in placebo-treated patients) is
a result of the passage of time and the associated regres-
sion to the mean,expected fluctuations in illness course,
and spontaneous remission.
1
Hrobjartsson and Gotzsche conducted a systematic
review of clinical trials in which patients were randomly
assigned to either placebo or no treatment.
11This review
included three clinical trials of depression in a total of 152
patients.A placebo was either pharmacological (eg, a
tablet), physical (eg, a manipulation), or psychological
(eg, a conversation).The authors found that, compared
with no treatment, placebo treatment had no significant
effect on binary outcomes, regardless of whether these
outcomes were subjective or objective.For the trials with
continuous outcomes,placebo offered a beneficial effect,
but the effect decreased with increasing sample size,indi-
cating a possible bias related to the effects of small trials.
The pooled standardized mean effect was significant for
the trials with subjective outcomes,but not for those with
objective outcomes.In trials involving treatment of pain,
however, placebo did have a beneficial effect, as indicat-
ed by a reduction in the intensity of pain.The authors
concluded that there was little evidence in general that
placebos had powerful objective clinical effects.Although
placebos had no significant effects on objective or binary
outcomes,they had possible small benefits in studies with
continuous subjective outcomes and for the treatment of
pain.They suggest that outside the setting of clinical tri-
als,there is no justification for the use of placebos as ther-
apeutic agents.Considering the limitations of the review,
the authors note that they did not assess the effect of the
patient–provider relationship, and hence could not rule
out a therapeutic psychological effect of this relationship,
which may be largely independent of any placebo inter-
vention.
11The physician–patient relationship,however,is
an important factor, especially in the treatment of ill-
nesses such as depression.
Nocebo effect
Nocebo literally means “I shall harm.”Nocebo respons-
es are adverse reactions to incidental aspects of treat-
ment; they are extremely common in patients and in
healthy volunteers in drug trials, and have important
implications for noncompliance with treatment.
6 Nega-
tive expectations of treatment or transient adverse
effects yielding conditioned responses to incidental fac-
tors may lead to severe adverse effects.
12
Proposed mechanisms underlying 
placebo response
Several mechanisms underlying a placebo response
have been proposed.These include the factors detailed
below.
Sociocultural factors
These include belief systems held by patients and/or physi-
cians/therapists,which may follow from ideas inconsistent
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106with Western scientific methods and thought.Historically,
medical anthropologists, psychiatrists, and psychologists
have studied magical,nonlogical beliefs,considering them
to be the key to placebo mechanisms.When a treatment
lacks a logical theory of action,the efficacy attributed to it
derives from culturally derived beliefs.
6,13
Factors associated with the treatment situation
Features of the treatment situation that are likely to con-
tribute to the placebo response include a thorough eval-
uation, an explanation for distress, an expert healer, a
plausible treatment, prior experience, expectation of
improvement, a healer’s commitment, enthusiasm, and
positive regard,and an opportunity to verbalize distress.
1
Ranga emphasizes the importance of understanding that
placebo does not really mean that no treatment was
delivered.
14 A component of treatment includes all the
contact between the investigator's team and the patient,
and suggests that this itself may have a therapeutic effect.
Thus,the myth that placebo suggests no treatment is not
entirely accurate; placebo basically implies no specific
treatment.
14 Some researchers have suggested that expec-
tations based on pill size, type, color, and number affect
outcome.
15,16 Multiple pills, larger pills, and capsules have
been shown to exert stronger placebo effects than single
pills,smaller pills,and tablets.Also,pill color may carry a
suggestion of potency and effect without prior cues.
6
Physician–patient relationship
The doctor–patient relationship confers significant
potency to the placebo response.
17,18 A good
doctor–patient relationship may help increase compli-
ance and maximize placebo effects, while minimizing
nocebo effects.
19 Transference, suggestion, guilt reduc-
tion,persuasion,cognitive dissonance,and conditioning
may have a role in the placebo effect.
4 Positive physi-
cian attitudes and good communication skills have been
reported to lower malpractice claims.
19 Physician con-
viction regarding a drug’s potency conveys a powerful
expectation to a hopeful patient and may be an impor-
tant “mediator of therapeutic effectiveness.”
17,18
Biological factors
The opioid system has been implicated in placebo
effects.
20 Sheline and colleagues also suggest that
platelet serotonin binding characteristics,but not patient
clinical characteristics, may distinguish depressed
patients who do and do not respond to placebo.
21
Mayberg and colleagues reported on a patient with post-
stroke depression, following an infarction of the left
basal ganglia.The patient’s depression remitted during a
6-week, double-blind trial, during which he received
placebo. Cortical serotonin-receptor binding was mea-
sured using 
11C-N-methylspiperone and positron emis-
sion tomography (PET) before and after the trial.The
authors found that cortical serotonin-receptor binding
increased in the left temporal cortex by more than 25%
during the trial (ie,with placebo in this case).The authors
conclude that the change in serotonin-receptor binding
and its relationship to the improvement in mood
observed in this patient are consistent with a correlation
between serotonin-receptor binding in the left temporal
cortex and severity of symptoms of depression.
22
Patterns of response in depression
A challenge in the treatment of depressive disorders is
to differentiate treatment-specific response from spon-
taneous remission or nonspecific response. Pattern
analysis has identified two types of response patterns to
antidepressants:true drug response (TDR) and placebo
pattern response (PPR).
23 TDR is characterized by a 2-
week delay in onset followed by persistent improvement
and PPR is characterized by early,transient,or nonper-
sistent improvement.
23,24 Patients with major depressive
disorder who have PPR are more likely to experience
relapse compared with those with TDR, and antide-
pressant continuation appears to be no more effective
in preventing depressive relapse than placebo.
23
Biological and cognitive differences in depressed
patients with TDR and PPR 
We conducted two studies at our center assessing dif-
ferences in biological and cognitive factors between
patients with TDR and PPR. In the first study, we eval-
uated the relationship between basal ganglia choline-
creatine ratios, as measured by in vivo localized proton
magnetic resonance spectroscopy (MRS), among
patients with TDR compared with those without TDR
following antidepressant treatment.
25We found a signif-
icant difference in the degree of change from baseline
to week 8 in choline-creatine ratios between the TDR
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107group (N=8) and the PPR/nonresponse group (N=7);
patients with TDR had a 20% increase in choline-crea-
tine ratios,and those with PPR/nonresponse had a 12%
decrease in choline-creatine ratios. Our data suggest
that TDR to fluoxetine treatment in depression may be
associated with an increase in choline-creatine ratios in
the basal ganglia.
25
In the second study, we examined the relationship
between cognitive factors and TDR (N=134) and PPR
(N=66) to antidepressant treatment.
26 We found that
after 8 weeks of treatment with an antidepressant,
patients with PPR had significantly lower scores on the
Perceived Stress Scale (PSS) and the Beck Hopelessness
Scale (BHS) (P<0.001 and P<0.05, respectively) com-
pared with patients with TDR. Our preliminary data
suggest that significant changes in cognitive/psycholog-
ical factors accompany PPR with antidepressant treat-
ment and differentiate it from the TDR pattern.
Predictors of placebo response 
in depression
Illness factors
Predictors of placebo response in depression include a
relatively short illness duration, a precipitating event,
depression of mild-to-moderate severity, and a good
response to previous antidepressant treatment.
27 Bialik
and colleagues
28 found that the placebo response rate
was the highest for women with a single episode of
depression (66.7%) and lowest for women with recur-
rent depressive episodes (13.3%).These authors also
found that, among patients experiencing their first
episode, placebo responders had lower Hamilton Rat-
ing Scale for Depression (HAMD) total scores at base-
line and lower ratings of psychomotor retardation than
nonresponders. For patients with a recurrence of an
episode, placebo responders had lower baseline ratings
of somatic anxiety.
28 Stewart and coworkers
29 found that
the presence of a psychosocial stressor in the context of
a depressive episode predicted a higher rate of placebo
response. Brown and colleagues
26 noted that improve-
ment with placebo was associated with a relatively short
illness, a precipitating event, depression of only moder-
ate global severity,and a good response to previous anti-
depressant treatment.
Assessments of severity of depression can predict place-
bo response;mild depressive episodes are more likely to
respond to placebo (rates as high as 70%) compared with
severe depressive episodes (rates closer to 30%).
1,30,31The
chronicity of the presenting episode is associated with a
low placebo response rate.
1 Depressed patients who are
ill for more than a year have lower placebo response rates
(usually less than 30%), and those with depressive
episodes of less than 3 months’ duration have placebo
response rates closer to 50%.
32 Klein proposed that the
relationship between placebo response and episode dura-
tion suggests that some of the placebo response may
merely represent spontaneous remission.
33
Patient factors
Patient demographic and personality attributes do not
consistently distinguish placebo responders and nonre-
sponders in antidepressant trials.
34 Fairchild and col-
leagues
35 have proposed that the tendency to respond
while receiving placebo should be viewed as normally dis-
tributed in the population: a smaller percentage of
patients never respond while receiving placebo, another
subset consistently do, and the majority of patients
respond under specific conditions of disease or treatment.
Biological factors
The dexamethasone suppression test is the only biolog-
ical variable that has been reported to predict placebo
response.
1 Patients who suppress cortisol secretion in
response to dexamethasone are found to be more like-
ly to respond to placebo (approximately 50%) than non-
suppressors (approximately 10%).
1
A recent study used quantitative electroencephalogra-
phy (QEEG) to examine brain function in 51 depressed
subjects receiving either an antidepressant (fluoxetine
or venlafaxine) or placebo, and sought to detect differ-
ences between medication and placebo responders.
36
The study assessed both QEEG power and cordance, a
new measure that reflects cerebral perfusion and is sen-
sitive to the effect of antidepressant medication.There
were no significant pretreatment differences in clinical
or QEEG measures among the four outcome groups.
Placebo responders, however, showed a significant
increase in prefrontal cordance starting early in treat-
ment that was not seen in medication responders (who
showed decreased cordance) or in medication nonre-
sponders or placebo nonresponders (who showed no
significant change).The authors conclude that “effec-
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tion that are distinct from those associated with antide-
pressant medication.If these results are confirmed,cor-
dance may be useful for differentiating between
medication and placebo responders.
36
Placebo response in antidepressant clinical trials
Double-blind, randomized, placebo-controlled, clinical
trials are recognized as the standard for establishing a
drug’s safety, efficacy, and dose–response relationships
for most major psychiatric disorders.
37-39 Justifications for
using placebo control groups include the fluctuating nat-
ural course of most psychiatric illnesses, the wide vari-
ability in placebo response across patient groups,and the
influence of psychosocial factors on treatment response.
37
The response rates for placebo in antidepressant clinical
trials range from 30% to 40%.
2,3 Among patients with
milder forms of depression and a relatively short episode
duration, the placebo response rate is close to 50% and
often indistinguishable from the response rate to antide-
pressants.
2 Recent antidepressant clinical trials have seen
a “placebo drift” in that the placebo response rate is
higher than in trials conducted 30 years ago,with a slight
lowering of the response to antidepressants and a sub-
stantial narrowing of the drug–placebo difference.
1 Pos-
sible explanations for this observation include the fact
that patient samples in recent trials are more likely to
have milder forms of depression than those in the older
studies.Also,since the newer antidepressants have fewer
side effects than the older ones, recent studies are more
truly double-blind; hence a positive bias toward the
active agents on the part of both patients and clinicians
has less influence over the outcome.
1 Rush
40 points out
that individuals most likely to enter placebo-controlled
trials may well be those most likely to respond to place-
bos, ie, patient self-selection is a key factor (into or out
of placebo-controlled studies). He further explains that
individuals most likely to agree to participate in placebo-
controlled trials are those who have less severe,less com-
plicated, less chronic, less disabling, and less treatment-
resistant illnesses,hence those more likely to respond to
placebos.
40
Strategies to minimize placebo response 
in antidepressant clinical trials
The substantial placebo response in depression reduces
the power of clinical trials and confounds treatment
decisions and the assessment of new therapies.
41 The
development of new antidepressant drugs is complicat-
ed by high placebo response rates, since new drugs are
required to demonstrate superior effectiveness to place-
bo or else they may be abandoned.
42,43 Due to the pauci-
ty of objective outcome measures in depression,it is par-
ticularly difficult to prove efficacy that is superior to
placebo.Thase
44 argues that since a third of antidepres-
sant published trials fail to demonstrate efficacy, new
strategies are needed to systematically reduce the
sources of variance.He suggests recruiting subjects with
moderate and severe illnesses, and implementing a 4-
week lead-in phase during which subjects receive psy-
choeducation about handling depression;these are both
steps aimed at reducing the number of patients still like-
ly to respond to placebo once the proper trial has
begun.
44 The 1- to 2-week, single-blind, placebo run-in
period prior to randomization was designed to lower the
placebo response in clinical trials; however, unfortu-
nately, it provides no advantage in acute-phase efficacy
trials.
3 Some researchers suggest that a variable dura-
tion,double-blind,placebo run with raters who are inde-
pendent of the design may reduce placebo responses
both in the week after randomization and over the
course of the study.
45 Using raters who can reliably
administer specific instruments over time,and assessing
interrater reliability over sequential assessments with
other sites is important.
10
Researchers have proposed potential alternatives to the
use of a placebo control group.These include add-on
studies, variable dose designs, establishing a priori
threshold effect sizes with an active comparison control,
and comparisons with historical controls.
46 Although
add-on designs do not obviate the need for placebo,they
eliminate placebo monotherapy.However,substantially
larger study populations are needed for sufficient power
to establish a drug–placebo difference because of the
contribution of the primary agent(s) to both drug and
placebo effects.Also, the use of add-on designs could
influence the duration of the trial.
46 Variable dose
designs allow for the possibility of establishing
dose–response relationships; however, it must be clear-
ly specified in the informed consent process that some
doses may not exert a therapeutic effect.Data regarding
effect sizes of drug versus placebo suggest that estab-
lishing a threshold effect size that an investigational
drug must reach or exceed in a trial with an active con-
Placebo response in depression - Sonawalla and Rosenbaum Dialogues in Clinical Neuroscience - Vol 4 . No.1 . 2002
109trol might obviate the need for a placebo control; how-
ever, the possibility of a robust placebo effect in both
treatment groups still cannot be excluded from such tri-
als. Comparing the efficacy results of an investigational
agent with historical data from previous trials has been
suggested as an alternative to placebo control groups.
The limitations of this approach include variability in
rating scales used,changes in diagnostic criteria,and dif-
ferent patient demographic and clinical characteristics
over time.
46
Some researchers suggest switching from placebo trials
to comparison trials as an alternative.
47 A double-
masked discontinuation trial with the new treatment as
an add-on or as a monotherapy has also been suggested
as an alternative.
40 Having established add-on efficacy
against placebos, and/or discontinuation efficacy in an
add-on or monotherapy trial,one could then proceed to
the classic randomized, double-masked, placebo-con-
trolled trial with the new treatment as a monotherapy
versus placebo. During the course of the add-on or dis-
continuation trials,one could attempt to identify specif-
ic clinical,historical,demographic,or other features that
appear to be associated with a high likelihood of drug
response.
40 Brown, however, suggests that the initial
treatment for selected depressed patients should be 4 to
6 weeks of placebo. Patients so treated should be
informed that the placebo pill contains no drug but that
this treatment can be helpful.
32
Ethical issues
Several ethical issues have been debated regarding the
use of placebo controls in clinical trials when effective
treatments are available.
48 Andrews emphasizes that
placebo-controlled trials are only appropriate when
there is no existing treatment for a disorder, otherwise
comparison trials are indicated.
41 Cochrane argues that
no new treatments should be introduced into medicine
unless they have been shown,in randomized controlled
trials, to be superior, or equivalent, to existing treat-
ments,and cheaper or safer.
49The Declaration of Helsin-
ki appears to restrict the use of placebos if an effective
treatment is known.
50
Quitkin and colleagues systematically reviewed the
methodological issues raised by such critiques,and con-
cluded that, despite the large response in the placebo
group,antidepressants produce specific additional ben-
efit.
51 Khan and colleagues found that in clinical trials,
depressed patients who were assigned to placebo were
not at a greater risk for suicide or suicide attempts than
those assigned to active treatment.
52 Miller
53 suggests
that four ethical standards must be satisfied for the
legitimate use of placebo controls in clinical research:
(i) placebo-controlled trials should have scientific and
clinical merit; (ii) risks should be minimized and justi-
fied by the anticipated benefits of generating clinically
relevant scientific knowledge and the expected benefits,
if any, to individual research subjects; (iii) patient vol-
unteers should give informed consent; and (iv) investi-
gators should offer short-term individualized treatment
optimization to patient volunteers after completion of
research participation.Miller
53 further concludes that if
scientific progress leads to the development of psychi-
atric medications that are highly effective with minimal
side effects,placebo-controlled trials that withhold such
treatment will become more difficult to justify. In that
case, the use of placebo-controlled trials will have
helped produce improvements in treatment that obvi-
ate the need and rationale for continued use of this
research design.
Clinical applications
Understanding the origin and mechanisms of placebo
response in depression has clinical implications. As
Andrews points out:“The size of response to the place-
bo might well be a bane to researchers and to the drug
industry,but properly handled,it is surely a boon to busy
clinicians and their patients.”
41 Considering that depres-
sion is the fourth major illness in the world in terms of
disease burden,
54 many patients and clinicians benefit
from any tool that maximizes therapeutic outcome.
Dago and Quitkin
4 suggest that, before deciding on
whether or not to prescribe an antidepressant,clinicians
should monitor the elements of the physician–patient
relationship that may affect the patient’s expectation or
hope of being helped by the medication.These authors
also recommend that a clinician follow those patients
who demonstrate an early clinical improvement without
antidepressant treatment until they have two unim-
proved weeks,and only then prescribe an antidepressant.
Systematic identification of a true drug response pattern
in patient samples, moreover, may help identify the
mechanism of action of medication and help clarify
ambiguous results derived from exclusive reliance on
end-point analyses in clinical trials.
24 In addition, differ-
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sions regarding long-term antidepressant treatment and
the approach to depressive relapses and recurrences.
24,55
Future research
Potential areas for research include identification of bio-
logical markers of placebo response in depression, and
developing and testing more sophisticated, alternative
research designs in clinical trials. Development of valid
biological tools to assess the efficacy of an antidepres-
sant,eg,functional neuroimaging,could also help great-
ly toward minimizing placebo response.
Conclusions
Depression is a placebo-responsive condition and the
mean response rates for placebo in antidepressant tri-
als range between 30% and 40%. It is important to
understand the differences between placebo response,
placebo effect, and PPR. Biological and cognitive dif-
ferences have been identified in patients with TDR
versus those with PPR. Mechanisms proposed for
placebo response in depression include sociocultural
factors,factors associated with the treatment situation,
the physician–patient relationship, and biological fac-
tors. Predictors of placebo response include duration
and severity of the depressive episode,the presence of
a precipitating event,a good response to previous anti-
depressant treatment, and suppression of cortisol
secretion in response to dexamethasone. Recent anti-
depressant clinical trials have seen a placebo drift,ie,a
higher placebo response rate compared with those
conducted earlier. Strategies suggested to lower the
placebo response in antidepressant clinical trials
include the use of alternative designs, such as add-on
studies, variable dose designs, and discontinuation
studies,establishing a priori threshold effect sizes with
an active comparison control, and comparisons with
historical controls. Ethical issues have been debated
regarding the use of placebo controls in antidepressant
clinical trials when effective treatments are available;
it is recommended that clinical trials including a place-
bo should meet certain ethical standards. Clinical
applications include monitoring placebo response to
maximize therapeutic outcome, and differentiating
TDR from PPR,and using it to guide clinical decisions
regarding long-term antidepressant treatment. Identi-
fication of biological markers of placebo response,
development and testing of more sophisticated, alter-
native research designs,and development of valid bio-
logical tools to assess the efficacy of an antidepressant
are some potential areas for future research. ❏
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La respuesta al placebo en la depresión
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constituye una condición con una alta respuesta
al placebo: las frecuencias promedio de respues-
ta al placebo en ensayos clínicos de antidepresi-
vos son entre el 30% y el 40%. Nosotros revisa-
mos la historia y la terminología del placebo y los
mecanismos propuestos que subyacen a la res-
puesta al placebo, incluyendo la relación médico-
paciente, los factores biológicos y socioculturales
y las situaciones en que se da el tratamiento.
Nosotros identificamos los predictores y patrones
de la respuesta al placebo de los pacientes depre-
sivos, ambos dentro y fuera del contexto de los
ensayos clínicos, y diferenciamos entre la verda-
dera respuesta al fármaco y el patrón de res-
puesta al placebo. Nosotros discutimos las estra-
tegias que se están desarrollando actualmente
para minimizar la respuesta al placebo, dado el
aumento en la varianza del placebo que ha sido
referido en ensayos recientes y las orientaciones
éticas que rigen la administración del placebo.
Las áreas potenciales para futuras investigaciones
incluyen la identificación de marcadores biológi-
cos de la respuesta al placebo, tales como neu-
roimágenes funcionales y electroencefalografía
cuantitativa, el desarrollo y evaluación de diseños
de investigación alternativos más sofisticados y el
diseño de herramientas biológicas válidas para
evaluar la eficacia de los antidepresivos.
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les études cliniques sur les antidépresseurs se
situent entre 30 et 40 %. Dans cet article, nous
passons en revue l’histoire et la terminologie du
placebo ainsi que les mécanismes proposés pour
expliquer la réponse placebo, qu’il s’agisse des
relations patient-médecin ou des facteurs biolo-
giques, socioculturels et des caractéristiques de la
conduite thérapeutique. Nous identifions les fac-
teurs prédictifs et les types de réponse placebo
chez les patients dépressifs, à la fois dans et en
dehors du contexte de l’essai clinique et nous dif-
férencions les réponses au traitement réel des
réponses au placebo. Nous discutons des straté-
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dérive de la réponse placebo dont les taux aug-
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dations éthiques sur les conditions d’administra-
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